Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study

Qing-Lei Zeng; Bing Li; Xue-Xiu Zhang; Yan Chen; Yan-Ling Fu; Jun Lv; Yan-Min Liu; Zu-Jiang Yu
November 2016
Gut & Liver;Nov2016, Vol. 10 Issue 6, p955
Academic Journal
Background/Aims: No clinical model exists to predict the occurrence of hepatocellular carcinoma in sustained virologic response-achieving (HCC after SVR) patients with chronic hepatitis C (CHC). Methods: We performed a case-control study using a clinical database to research the risk factors for HCC after SVR. A predictive model based on risk factors was established, and the area under the receiver operating characteristic curve (AUC) was calculated. Results: In the multivariate model, an initial diagnosis of compensated cirrhosis and post-SVR albumin reductions of 1 g/L were associated with 21.7-fold (95% CI, 4.2 to 112.3; p<0.001) and 1.3-fold (95% CI, 1.1 to 1.7; p=0.004) increases in the risk of HCC after SVR, respectively. A predictive model based on an initial diagnosis of compensated cirrhosis (yes, +1; no, 0) and post- SVR albumin ≤36.0 g/L (yes, +1; not, 0) predicted the occurrence of HCC after SVR with a cutoff value of >0, an AUC of 0.880, a sensitivity of 0.833, a specificity of 0.896, and a negative predictive value of 0.956. Conclusions: An initial diagnosis of compensated cirrhosis combined with a post-SVR albumin value of ≤36.0 g/L predicts the occurrence of HCC after SVR in patients with CHC.


Related Articles

  • Changes in serum complement components after 48 weeks of entecavir treatment in hepatitis B cirrhosis patients. ZHANG, Xuehua; LI, Zhongping // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;May2013, Vol. 29 Issue 5, p339 

    Objective To investigate the effects of entecavir treatment on serum complement components, C3 and C4, in patients with hepatitis B ciirhosis ad to determine their relation with treatment response. Methods Ninety - eight patients with hepatitis B ciirhosis who were treated with entecavir ( 10 mg...

  • Antiviral Treatment of HCV Carriers with Persistently Normal ALT Levels. Puoti, Claudio; Bellis, Lia; Galossi, Alessandra; Guarisco, Riccardo; Nicodemo, Sabino; Spilabotti, Lucia; Dell' Unto, Orlando // Mini Reviews in Medicinal Chemistry;Feb2008, Vol. 8 Issue 2, p150 

    Approximately 30% of patients with chronic HCV infection show persistently normal alanine aminotransferase levels (PNAL). The prevalence of HCV carriers with normal liver seems to be very low (less than 15-20%). Liver disease is usually minimal/mild and fibrosis is generally absent or minimal,...

  • Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. Moon, Chansoo; Jung, Kyu; Kim, Do; Baatarkhuu, Oidov; Park, Jun; Kim, Beom; Kim, Seung; Ahn, Sang; Han, Kwang-Hyub // Digestive Diseases & Sciences;Feb2015, Vol. 60 Issue 2, p573 

    Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to...

  • A Cure for the High Cost of Hepatitis C Virus Treatment. Etzion, Ohad; Ghany, Marc G. // Annals of Internal Medicine;5/5/2015, Vol. 162 Issue 9, Following p660 

    The authors discusses a study by B. P. Linas and others, published in the issue, regarding cost-effectiveness of the drug sofosbuvir-based regimens for treatment of hepatitis C virus (HCV) genotype 2 or 3 infection. They mentions the findings of the study which reveals that sofosbuvir-based...

  • Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis. Grizzi, Fabio; Desmet, Valeer J. // Indian Journal of Medical Research;Aug2014, Vol. 140 Issue 2, p160 

    The author discusses research studies on the prevalence of hepatitis B virus (HBV) related cirrhosis in India. Topics discussed include the interpretation of liver biopsy, importance of monitoring the genotypic resistance of HBV to antiviral agents, identification of serum alanine...

  • Rare complication of variceal embolization: a novel case. Oza, Veeral M.; Levine, Edward; Kirkpatrick III, Robert // Journal of Interventional Gastroenterology;7/ 1/2012, Vol. 3 Issue 3, p113 

    A letter to the editor is presented about the case of a 61-year-old female with a history of cirrhosis secondary to Hepatitis C who developed an embolization coil eroding thru a duodenal varix.

  • HEPATITIS C CIRRHOSIS--NOT NECESSARILY A TERMINAL DISEASE. Saeian, Kia; Reddy, K. Rajender; Johnson, David // American Journal of Gastroenterology;Aug1998, Vol. 93 Issue 8, p1386 

    Provides information on a study that evaluated the morbidity and survival of patients with compensated, histologically proven cirrhosis from hepatitis C virus infection. Methodology of the study; Results and discussion of the study.

  • Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a Hofer, Harald; Bankl, Hans C.; Wrba, Friedrich; Steindl-Munda, Petra; Peck-Radosavljevic, Markus; Österreicher, Christoph; Mueller, Christian; Gangl, Alfred; Ferenci, Peter // American Journal of Gastroenterology;Nov2002, Vol. 97 Issue 11, p2880 

    OBJECTIVES:The aim of this study was to prospectively investigate the prevalence of hepatic steatosis in chronic hepatitis C patients with respect to viral genotype, hepatic iron concentration, total body iron, body mass index, and serum lipid parameters. Furthermore, the effect of hepatitis C...

  • Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Fattovich, G.; Olivari, N.; Pasino, M.; D'Onofrio, M; Martone, E.; Donato, F. // Gut;Jan2008, Vol. 57 Issue 1, p84 

    Objective: To assess risk factors for liver-related death, we re-evaluated, after a median follow-up of 25 years, a cohort of 70 Caucasian patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis (CH) at presentation. Methods: Follow-up studies included clinical and ultrasound...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics